Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside
Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential opportunity. Click for more on TECX.
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 40.65%
Tectonic Therapeutic, Inc.’s TECX share price has dipped by 40.65%, which has investors questioning if this is right time to buy.
Tectonic Therapeutic reports ‘positive’ data from Phase 1b trial for TX45
Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate,
Tectonic Therapeutics’ (TECX) Stock Rockets: What’s Behind the Surge?
Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its lead product candidate,
Tectonic Therapeutic stock soars on positive trial data
Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF).
Tectonic Therapeutic Shares Hit 52-Week High After Positive Trial Data
Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein.
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with
Tectonic stock booms on phase Ib heart data
Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) were trading at $55, up $29.28, or 113%, on positive interim data from the phase Ib acute hemodynamic trial of its lead product candidate, TX-45. Results with the long-acting,
Tectonic jumps on positive data from early-stage trial for lead asset
Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its prespecified goals in a group of patients with pulmonary hypertension.
Tectonic Therapeutic (NASDAQ:TECX) Trading 6.7% Higher Following Analyst Upgrade
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report)’s share price traded up 6.7% on Friday after Wells Fargo & Company raised their price target on the stock from $79.00 to $112.00. Wells Fargo & ...
BioWorld2d
Wall Street relaxin as Tectonic plates up phase Ib heart data
Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...
Seeking Alpha28d
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic Therapeutic (NASDAQ:TECX) discovers antibody therapeutics for GPCRs. Founded in 2019 by Andrew Kruse and Timothy Springer, the company uses its GEODe platform to engineer biologics to ...
Optimistic Outlook for Tectonic Therapeutic’s TX45: A Promising Candidate for Unmet Medical Needs
Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...